Recombinant parathyroid hormone (1-34)

重组人甲状旁腺素1-34 (上海中科生龙达生物)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant parathyroid hormone (1-34)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionParathyroid hormone receptor agonistsOsteogenesis stimulantsCalcium sensing receptor antagonists +[4] 
TargetsCalcium sensing receptorParathyroid hormone receptor
Therapy Area/IndicationsOsteoporosis, Postmenopausal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaPending
Originator CompaniesShanghai Zhongke Shenglongda Biotechnology (Group) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Inactive CompaniesShanghai Zhongke Shenglongda Biotechnology (Group) Co Ltd
Active IndicationsN/A
Inactive IndicationsOsteoporosis, Postmenopausal

Other Information

ATC CodeN/A
Related LinksN/A